Galmed Pharmaceuticals (NASDAQ: GLMD) sets Oct. 28, 2025 shareholder meeting

Rhea-AI Filing Summary

Galmed Pharmaceuticals Ltd. reports it will hold its Annual General Meeting of Shareholders on October 28, 2025, at 4:00 p.m. (Israel time) at the offices of Meitar | Law Offices in Ramat Gan, Israel. The company has provided a Notice of the Annual General Meeting and Proxy Statement as Exhibit 99.1 and a Proxy Card as Exhibit 99.2. This report on Form 6-K is also incorporated by reference into Galmed’s existing Registration Statements on Form S-8 and Form F-3.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 09/19/2025 - 04:05 PM Learn about SEC filing dates

FAQ

When is Galmed Pharmaceuticals (GLMD) holding its 2025 Annual General Meeting?

Galmed Pharmaceuticals Ltd. will hold its 2025 Annual General Meeting of Shareholders on October 28, 2025, at 4:00 p.m. (Israel time).

Where will Galmed Pharmaceuticals (GLMD) hold the 2025 shareholder meeting?

The meeting will take place at Meitar | Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan, 5250608, Israel.

What documents are included with Galmed’s 2025 Annual General Meeting notice?

The company attached a Notice of the Annual General Meeting and Proxy Statement as Exhibit 99.1 and a Proxy Card as Exhibit 99.2.

How is this Galmed (GLMD) Form 6-K used in the company’s registration statements?

This Form 6-K is incorporated by reference into Galmed’s Registration Statements on Form S-8 and Form F-3 identified by their registration numbers.

Who signed the Galmed Pharmaceuticals (GLMD) Form 6-K for the 2025 meeting?

The Form 6-K was signed on behalf of Galmed Pharmaceuticals Ltd. by Allen Baharaff, President and Chief Executive Officer.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of September 2025

001-36345

(Commission File Number)

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

c/o Meitar Law Offices Abba Hillel Silver Rd.,

Ramat Gan, 5250608

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Galmed Pharmaceuticals Ltd. (the “Company”) announces that it will hold an Annual General Meeting of Shareholders on October 28, 2025, at 4:00 p.m. (Israel time) at the offices of Meitar | Law Offices, legal counsel to the Company at 16 Abba Hillel Silver Rd., Ramat Gan, 5250608, Israel. A copy of the Notice of the Annual General Meeting of Shareholders and Proxy Statement and the Proxy Card are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration Nos. 333-206292, 333-227441 and 333-284163) and the Company’s Registration Statement on Form F-3 (Registration Nos. 333-272722 and 333-283241).

Exhibit Index

Exhibit No.		Description
99.1		Notice of the Annual General Meeting of Shareholders and Proxy Statement
99.2		Proxy Card

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Galmed Pharmaceuticals Ltd.
Date: September 19, 2025	By:	/s/ Allen Baharaff
		Allen Baharaff
		President and Chief Executive Officer

-3-